

SURMOUNT-3 Trial: Phase 3 Trial Investigating Tirzepatide in Adults with Overweight/Obesity and at Least 1 Obesity-Related Complication (excluding type 2 diabetes)



Patients with BMI ≥ 30 or ≥ 27 kg/m² who achieved $\geq 5\%$ weight reduction at the end of the lead-in period (N=579)

